Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Tilray

Is Tilray Stock a Buy on Positive Cannabis Data?

Tilray reported a positive update for its chemo-related drug.

Barchart

1 Cannabis Stock I Would Buy, and One I Would Avoid

The cannabis industry is rapidly growing, but will Canadian players be able to keep up?

Barchart

Cresco vs. Tilray: Which Cannabis Stock Is a Better Buy?

Despite lingering regulatory challenges, the cannabis market is well-positioned for a steady expansion. Penny stock Cresco's solid financials and growth potential have won over analysts, while Tilray failed to impress with last quarter’s record revenue.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Growth Stocks With 32% to 77% Upside in 2024

While AI stocks are the center of attention right now, many other growth stocks in various industries are going unnoticed. These stocks may benefit investors in the long run.

Barchart

Canopy Growth Stock Spikes, Weed Stocks Still Trade Higher Days After VP Harris Comments

Canopy Growth stock led weed stocks higher early Wednesday. Shares continue rallying on Vice President Kamala Harris' call to reclassify marijuana.

Investors Business Daily

Tilray Getting Out Of Its Own Way? - The Rebel's Edge

Jon and Pete Najarian join forces to discuss and debate their favorite topics, including the hottest stock-specific news and sports! Today: and the NCAA National Champs

The Street

Bullish or Bearish: 3 Pharma Options

The pharmaceutical industry’s robust outlook is driven by high healthcare spending globally, consistent R&D efforts, and the rapid adoption of advanced digital technologies. So, let’s analyze if investors should adopt a bullish or bearish stance on pharma stocks such as Tilray Brands (TLRY), CytomX Therapeutics (CTMX), and Wave Life Sciences…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Cannabis stocks get boost from good news out of the Biden administration

Cannabis companies like Tilray and Canopy Growth jumped double digits Thursday on the news.

The Street

Anheuser-Busch is selling 8 of its beloved brands as Bud Light drama plagues its business

The beer company is expected to finalize the massive sale by the end of 2023.

The Street

Key Cannabis Exec Changes Investors Should Know About: ScottsMiracle Gro, Tilray, Metrc, & Willow Industries

ScottsMiracle-Gro Nominates Edith Avilés To Board Of Directors

Benzinga

Jim Cramer Is Bullish On Cannabis Stocks Ahead Of Midterm Elections: 'I Say Buy Tilray'

Mad Money host Jim Cramer said last week during a Lightning Round segment that now is a good time to invest in Tilray.

Benzinga

What's Going On With Recreational Cannabis Sales In Canada? Analyst Examines The Situation

Sales growth in Canada appears to be stagnating for the cannabis sector.

Benzinga

Germany To Allow Adults To Possess An Ounce Of Cannabis And More In New Legalization Plan

A week after Germany's cannabis legalization measures were leaked, Health Minister Karl Lauterbach presented a plan to Chancellor Olaf Scholz's cabinet on Wednesday, reported Deutsche Welle.

Benzinga

Aurora & Tilray Better Positioned Than Other Cannabis Operators For Germany's Imminent Market Launch, Here's Why

A draft of the German government's cannabis legalization measure, which was leaked on Wednesday, indicates the EU country is getting close to legalizing retail distribution, possession a

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Tilray Stock Soars Then Returns To Earth On Biden's Cannabis Pardon News, This Analyst Remains Neutral

On the heels of President Biden’s historic announcement that he was pardoning all federal marijuana possession convictions, Cantor Fitzgerald's

Benzinga

S&P 500 Gives Up Early Week Gains Following Latest Jobs Report: Is A Recession Looming?

After a strong two-day rally to start October, the SPDR S&P 500 ETF Trust (NYSE: SPY) gave up some of its gains on Friday following a mixed U.S. jobs report.

The Street

Tilray Looks to Germany as Canada's Cannabis Industry Falters

High inventory and increased competition is making Canadian cannabis companies look elsewhere for growth.

Benzinga

Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day Session

Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 108% to $3.3943 on abnormally-high volume. The company released its October investor presentation yesterday.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Trading Cannabis Stocks on Earnings Reports, Biden Pardon

Cannabis stocks were flying higher Thursday but are in retreat on Friday. Here's how to trade three key names.

Benzinga

Canopy Growth, Tilray Pull Back After Enjoying Surge Following Biden's Pardon: What's Up With These Cannabis Stocks?

Canopy Growth Corp. (NASDAQ: CGC) and Tilray Brands Inc. (NASDAQ: TLRY) were plunging over 13% and 11%, respectively, at one point Friday after skyrocketing on Thursday.

Benzinga

Levi Strauss, Tilray Brands And Some Other Big Stocks Moving Lower On Friday

U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording losses in today’s session.

Investors Business Daily

Cannabis Stocks Surge, Reverse On Biden Marijuana Possession Pardons

Cannabis stocks dropped Friday after President Joe Biden on Thursday announced pardons for thousands of people convicted of marijuana possession under federal law. The president called on governors to take similar action for state offenses. Biden also said his administration will review whether cannabis should remain in its current federal…

Benzinga

Tilray Net Loss Nearly Doubles From Year Ago, But Biden Marijuana Pardons Keep The Stock Up

Canadian marijuana giant Tilray Brands, Inc. (NASDAQ: TLRY) (TSX:TLRY) reported Friday financial results for the first fiscal quarter ended August 31, 2022, with net revenue of $153.2 million, which compares to revenue of $168.02 million for the same period last year.

Benzinga

Want Exposure To The Canadian Recreational Cannabis Market? These Are The 3 Best Picks, According To A Cantor Analyst

In a recent analyst note, Pablo Zuanic from Cantor Fitzgerald offered an update on the performance of Canada’s cannabis Licensed Producers in the August quarter, based on data obtained by the market scanner Hifyre.

The Street

Cannabis Company Tilray Just Made a Major Blunder

A Tilray press release last week seems to have caused some dismay among Germany's drug regulators.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.